Integrative analysis of plasma small-molecule and gut-microbiome markers of sarcopenia in a pilot study within an Indian cohortOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This pilot study applied an integrative multi-omics workflow to identify plasma metabolite, lipid, and gut-microbiome signatures associated with sarcopenia. Sarcopenia is the age-related decline in muscle mass and strength, and the researchers combined plasma metabolomics, lipidomics, and 16S rRNA gut-microbiome sequencing to look for markers linked to the condition. Participants were classified as sarcopenic or non-sarcopenic using EWGSOP2 criteria, which incorporate grip strength, chair rise time, psoas muscle cross-sectional area on CT, and the SARC-F screening score.
Who was studied?
The cohort consisted of forty community-dwelling older adults, aged 60 to 87 years, from an Indian population. Of these, fifteen were classified as sarcopenic and twenty-five as non-sarcopenic based on EWGSOP2 criteria. This was a pilot study, so the sample size was small and intended to generate preliminary integrative findings rather than definitive population-level estimates.
What were the most important findings?
Dominant hand grip strength was the strongest clinical predictor of sarcopenia, with an AUROC of 0.93. Sarcopenic subjects showed higher systemic inflammation, reflected in an elevated neutrophil-to-lymphocyte ratio, and elevated plasma arachidonic acid compared to non-sarcopenic subjects. Thirteen lipid species, primarily lysophosphatidylcholines, lysophosphatidylethanolamines, and hexosylceramides, were identified as discriminating between the two groups, and a support vector machine model with recursive feature elimination was used to identify these discriminative metabolites, with gut microbiome profiles correlated against the metabolite patterns. The abstract as provided does not mention Faecalibacterium prausnitzii, butyrate, or anti-inflammatory commensals specifically.
What are the greatest implications of this study?
The findings suggest that sarcopenia in older adults is accompanied by a distinct signature of systemic inflammation, altered lipid metabolism, and arachidonic acid elevation that can be captured through integrative multi-omics profiling. Combining clinical measures like grip strength with plasma metabolomic, lipidomic, and gut-microbiome data may help identify biological markers of sarcopenia beyond physical function tests alone. Because this was a small pilot study within an Indian cohort, larger and more diverse studies would be needed before these metabolite, lipid, and microbiome signatures could be used as validated diagnostic or monitoring tools.